Related Experiment Video
Updated: Feb 25, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Continuous Petri Nets and microRNA Analysis in Melanoma
Abstract:
Personalized target therapies represent one of the possible treatment strategies to fight the ongoing battle against cancer. New treatment interventions are still needed for an effective and successful cancer therapy. In this scenario, we simulated and analyzed the dynamics of BRAF V600E melanoma patients treated with BRAF inhibitors in order to find potentially interesting targets that may make standard treatments more effective in particularly aggressive tumors that may not respond to selective inhibitor drugs. To this aim, we developed a continuous Petri Net model that simulates fundamental signalling cascades involved in melanoma development, such as MAPK and PI3K/AKT, in order to deeply analyze these complex kinase cascades and predict new crucial nodes involved in melanomagenesis. The model pointed out that some microRNAs, like hsa-mir-132, downregulates expression levels of p120RasGAP: under high concentrations of p120RasGAP, MAPK pathway activation is significantly decreased and consequently also PI3K/PDK1/AKT activation. Furthermore, our analysis carried out through the Genomic Data Commons (GDC) Data Portal shows the evidence that hsa-mir-132 is significantly associated with clinical outcome in melanoma cancer genomic data sets of BRAF-mutated patients. In conclusion, targeting miRNAs through antisense oligonucleotides technology may suggest the way to enhance the action of BRAF-inhibitors.
Insights
This study reveals that targeting microRNAs (miRNAs), specifically hsa-mir-132, can enhance BRAF inhibitor efficacy in melanoma. Modulating miRNA levels offers a new strategy for aggressive, treatment-resistant cancers.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- Personalized targeted therapies are crucial for cancer treatment, but new interventions are needed for aggressive tumors.
- BRAF inhibitors are used for BRAF V600E melanoma, yet some tumors remain resistant.
- Understanding complex signaling pathways is key to improving cancer therapy effectiveness.
Purpose of the Study:
- To simulate and analyze signaling dynamics in BRAF V600E melanoma patients treated with BRAF inhibitors.
- To identify novel therapeutic targets for enhancing standard treatments in aggressive melanoma.
- To investigate the role of microRNAs in melanoma development and treatment response.
Main Methods:
- Development of a continuous Petri Net model to simulate MAPK and PI3K/AKT signaling cascades.
- Analysis of signaling dynamics to predict crucial nodes in melanomagenesis.
- Utilizing the Genomic Data Commons (GDC) Data Portal for clinical data analysis.
Main Results:
- The model identified hsa-mir-132 as a microRNA that downregulates p120RasGAP expression.
- High p120RasGAP levels were shown to decrease MAPK and PI3K/AKT pathway activation.
- Genomic data analysis confirmed a significant association between hsa-mir-132 and clinical outcomes in BRAF-mutated melanoma patients.
Conclusions:
- Targeting microRNAs, such as hsa-mir-132, may enhance the efficacy of BRAF inhibitors in melanoma.
- Antisense oligonucleotides technology presents a potential strategy for miRNA-based cancer therapy.
- This approach could lead to more effective treatments for aggressive and resistant melanoma cases.
